

Mutlu Dogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2088183/publications.pdf>

Version: 2024-02-01

20
papers

191
citations

1163117

8
h-index

1058476

14
g-index

20
all docs

20
docs citations

20
times ranked

349
citing authors

#	ARTICLE	IF	CITATIONS
1	The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 356-362.	1.3	2
2	Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. <i>Journal of Chemotherapy</i> , 2022, , 1-8.	1.5	0
3	â€œSwords and Shieldsâ€ against COVID-19 for patients with cancer at â€œcleanâ€ and â€œpandemicâ€ hospitals: are we ready for the second wave?. <i>Supportive Care in Cancer</i> , 2021, 29, 4587-4593.	2.2	5
4	Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 611-621.	2.4	0
5	Alectinib continuation during COVID 19 â€˜antiviralâ€™™ treatment: Risk or benefit?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522110201.	0.9	2
6	Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. <i>Cancer Investigation</i> , 2021, 39, 473-481.	1.3	9
7	Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. <i>Future Oncology</i> , 2021, 17, 4447-4456.	2.4	26
8	Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit. <i>Irish Journal of Medical Science</i> , 2020, 189, 805-810.	1.5	4
9	The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e23168.	1.0	0
10	Is there any correlation among MKK4 <i>(mitogen-activated protein kinase kinase 4)</i> expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 851-859.	3.1	1
11	Neutrophilâ€lymphocyte ratio, plateletâ€lymphocyte ratio, neutrophilâ€platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?. <i>Current Medical Research and Opinion</i> , 2018, 34, 857-863.	1.9	19
12	The relationship between plateletâ€lymphocyte ratio, neutrophilâ€lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatin plus 5 Fluorourasil Regimen: A single institute experience. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 320.	1.1	17
13	Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3997-4002.	1.2	44
14	The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. <i>Medical Oncology</i> , 2014, 31, 232.	2.5	6
15	Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. <i>Medical Oncology</i> , 2012, 29, 2021-2026.	2.5	10
16	Relationship Between Antimetabolite Toxicity and Pharmacogenetics in Turkish Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1553-1556.	1.2	8
17	A rare gastric neoplasm: gastric medullary carcinoma. <i>Medical Oncology</i> , 2011, 28, 945-947.	2.5	6
18	Fifty-one Kaposi sarcoma patients. <i>Clinical and Translational Oncology</i> , 2010, 12, 629-633.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Intestinal malignant melanoma presenting with small bowel invagination: A case report. Turkish Journal of Gastroenterology, 2010, 21, 439-442.	1.1	7
20	Venous Thromboembolism in Patients with Cancer and Its Relationship to the Coagulation Cascade and Vascular Endothelial Growth Factor. Supportive Cancer Therapy, 2005, 3, 28-34.	0.3	15